Madrigal Pharmaceuticals, Inc. MDGL Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s stock-based comp?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported stock-based comp of $34.02M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s stock-based comp increased by 62.5% year-over-year, from $20.93M to $34.02M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s stock-based comp has grown at a 38.2% compound annual growth rate (CAGR), from $26.87M to $98.13M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock.
- How do you interpret stock-based comp?
- Higher levels indicate significant equity-based incentives, which may lead to shareholder dilution.
- How does stock-based comp compare across companies?
- Common in high-growth biotech and tech sectors; often analyzed relative to total revenue or market cap.